Protox lines up $35M for BPH program

Warburg Pincus will invest up to $35 million in Canada's Protox Therapeutics, fueling its new therapy for benign prostatic hyperplasia as it advances into late-stage trials. The investment group will take a 21 percent stake in Protox in exchange for the first $10 million tranche. The additional money is scheduled to arrive in the next year. Story